Abeona Therapeutics Inc., a company developing gene therapies for the two most common types of Sanfilippo syndrome, also known as mucopolysaccharidosis III (MPS III), has reported early progress on both programs. ABO-102 (AAV-SGSH), the more advanced candidate for MPS IIIA, showed time and dose-dependent responses in biomarkers and, following a recent FDA allowance, could soon be used to treat patients earlier in the course of their disease, the company said.